Post-infarction ventricular aneurysm

Article written and reviewed by Dr Luca Moretti

A post-infarction ventricular aneurysm is a circumscribed, permanent, and generally broad dilation of a ventricular wall that has undergone transmural necrosis. The wall contains thinned myocardial tissue progressively replaced by scar, remains continuous with the ventricular layers, and is akinetic or dyskinetic; this true aneurysm belongs to ischemic remodeling. It is not a contained cardiac rupture and does not automatically share the urgency of a pseudoaneurysm.
The classic location is anterior or anteroapical after a large infarction in the left anterior descending artery territory. The sac alters ventricular shape and volume, removes part of the cavity from effective contraction, and increases stress on the remaining portion; systolic dyskinesia may reduce output beyond what the amount of scar suggests. Geometry, function, and viability of the remaining myocardium are therefore more informative than external size alone.

Most aneurysms recognized today are chronic and do not carry an imminent risk of rupture because a mature scar has different strength from acutely necrotic myocardium. The dominant clinical consequences are heart failure, ventricular tachycardia, ischemic mitral regurgitation, intracavitary thrombus, and embolism. Functional risk prevails over rupture risk. Recent expansion or an uncertain morphological diagnosis nevertheless requires exclusion of a pseudoaneurysm.
The aneurysm is not in itself an indication for surgery. Pharmacological therapy, revascularization, anticoagulation, ablation, a defibrillator, and ventricular reconstruction address different problems and are selected on the basis of symptoms, ischemia, arrhythmias, thrombus, and anatomy; multidisciplinary assessment prevents interventions driven by the image alone. The aim is to improve prognosis and quality of life while preserving functional ventricular volume.

Frequency estimates have decreased in the era of primary PCI, but vary because historical and contemporary studies use different definitions and imaging times. Administrative registries underestimate silent forms, whereas imaging cohorts select more extensive infarctions; contemporary frequency is not represented by a universal percentage. Every epidemiological figure must specify the population, infarct location, and diagnostic criterion used.

Etiology, risk factors, pathogenesis, and pathophysiology

The process begins with an infarction sufficiently extensive and deep to compromise the full thickness of the wall. In the first hours, the necrotic zone may dilate and thin without further necrosis, a phenomenon termed infarct expansion; the noninfarcted ventricle subsequently changes shape and size. Early expansion prepares the anatomical substrate. The scar stabilizes the wall but fixes a mechanically inefficient geometry.
Timely reperfusion limits the area at risk, transmural extent, and aneurysm formation. Late presentation, proximal left anterior descending artery occlusion, a large akinetic area, and absence of collaterals instead increase the probability without inevitably determining the outcome; myocardial salvage is the most effective prevention. Technically successful PCI may nevertheless fail to recover tissue that was already necrotic before the vessel was opened.

Microvascular obstruction and intramyocardial hemorrhage are markers of severe injury on magnetic resonance. Failed tissue perfusion after epicardial reopening prolongs edema and inflammation, hinders orderly healing, and is associated with adverse remodeling; impaired microcirculation explains part of the variability after reperfusion. Not every patient with TIMI 3 flow has the same structural risk.
According to Laplace's law, an increased cavity radius and reduced wall thickness increase wall stress. The infarcted region expands further, while viable myocardium must generate more force to maintain output, fueling dilation and oxygen consumption; wall stress creates a remodeling cycle. Blood pressure control and neurohormonal therapy seek to interrupt it, although they cannot reverse a mature scar.

The aneurysmal segment may expand during systole instead of contributing to ejection. Some contractile energy distends the sac and is returned during diastole without producing useful forward flow, reducing efficiency and stroke volume; paradoxical volume aggravates global dysfunction. The impact depends on the ratio between the aneurysm and the residual cavity, not solely on the sac's dimensions.
Dilation displaces the papillary muscles and widens the mitral annulus, reducing leaflet coaptation and causing functional regurgitation. Increased filling pressures cause congestion, while sympathetic and renin-angiotensin-aldosterone activation promotes further remodeling. Mitral regurgitation may become a hemodynamic amplifier. It must be quantified together with ventricular geometry and not treated as a separate finding.

The heterogeneous scar and border zone contain surviving myocardial bundles separated by fibrosis. Slow conduction and unidirectional block permit reentry circuits, while extensive akinesia promotes stasis and thrombus; the arrhythmic substrate and thrombotic substrate arise from the same lesion but require distinct strategies. Ejection fraction, scar anatomy, and thrombus morphology complete risk estimation.
Healing depends on the balance among matrix degradation, collagen deposition, and mechanical load. Inflammatory activation necessary to remove necrotic tissue may become unfavorable if persistent, while disorganized repair leaves a heterogeneous border zone; scar biology links remodeling and arrhythmias. There is currently no specific antifibrotic therapy capable of selectively preventing aneurysm in humans.

Repeated infarctions in the same territory may enlarge an established scar, while new ischemia at the viable border worsens contractility and geometry without necessarily enlarging the sac uniformly. Prolonged tachyarrhythmias and excessive pressure load may also accelerate global dilation; multifactorial progression does not depend solely on the initial event; therefore, coronary stability and control of comorbidities remain part of chronic aneurysm therapy.

Pathological anatomy, classification, and evolution

Macroscopically, a true aneurysm shows a generally broad transition from the ventricular cavity to the dilated region. The wall is thin, fibrous, and often adherent to the pericardium; internally it may be lined by organized laminated thrombus; the scar wall retains endocardium and myocardial remnants; this histological continuity distinguishes it from a cavity formed outside a contained rupture.
The anteroapical location predominates and reflects the territory of large left anterior descending artery infarctions. Inferior, basal, or posterior aneurysms are less common and require particular attention to the differential diagnosis with pseudoaneurysm, which favors inferior and posterolateral locations; anatomical location changes pretest probability. It is not, however, sufficient to establish wall composition without adequate imaging.

Motion is described as akinesia when the wall neither thickens nor moves inward and dyskinesia when it bulges paradoxically during systole. Some sacs have mixed components, while the surrounding zone may be hypokinetic but viable; regional motion guides functional quantification. The word aneurysm alone does not replace description of the neck, volume, wall, and residual segment.
There is no single international dimensional threshold that separates aneurysm, remodeling, and a large dyskinetic area in every technique. Definitions based on contour, percentage of circumference, or motion have been used in different studies, making many epidemiological estimates incomparable; the operational definition must be reported. An apparent change may result from method, loading, rate, or measurement plane.

Initial evolution includes edema, thinning, and expansion; during subsequent weeks, fibroblasts, collagen, and remodeling transform necrosis into scar. After maturation, spontaneous rupture of a true aneurysm is rare, unlike the wall of a pseudoaneurysm; fibrous maturation changes the risk profile. A sac observed very early must be reassessed if the anatomy is not unequivocal.
Mural thrombus may begin as a laminated deposit and organize by adhering to the endocardial surface. Some calcifications indicate chronicity; other areas may remain free of thrombus despite dyskinesia because flow and coagulation status vary among patients; intracavitary thrombosis is not an obligatory component. Its absence on one examination does not justify indiscriminate surveillance if clinical risk is low.

Over the long term, volume may stabilize or increase along with dilation of the remaining ventricle. Recurrent ischemia, uncontrolled blood pressure, and mitral regurgitation accelerate deterioration, while heart failure therapy may promote reverse remodeling of viable regions; the volume trajectory is more useful than one measurement. Repeat imaging should answer a clinical question and use a comparable technique.
A congenital ventricular diverticulum enters the differential diagnosis when the protrusion has a myocardial wall, synchronous contraction, and no ischemic scar. Fibrous, noncontractile, or apical diverticula may nevertheless be harder to distinguish by echocardiography alone; the ischemic context and tissue characterization resolve many uncertainties. A history from birth, normal coronary arteries, and absence of post-infarction late enhancement favor a nonacquired origin.

Signs and symptoms

Some aneurysms are discovered during post-infarction follow-up in patients without new symptoms. The finding has a different meaning if global function is preserved, there is no thrombus or arrhythmia, and dimensions remain stable; the asymptomatic phenotype does not automatically require intervention. It instead requires rigorous secondary prevention and definition of findings that might alter follow-up.
Exertional dyspnea, orthopnea, edema, and fatigue result from reduced output and increased filling pressures. Severity does not always correspond to ejection fraction because mitral regurgitation, right ventricular function, rhythm, and peripheral adaptation influence functional capacity; chronic heart failure is an integrated syndrome. The aneurysm's specific contribution is estimated by comparing geometry, hemodynamics, and residual myocardium.

Angina may result from residual coronary disease, ischemia at the aneurysm border, or increased demand of viable myocardium. It does not prove that the sac should be removed and requires assessment of revascularizability separate from ventricular reconstruction. Residual ischemia must be localized. A complete scar does not benefit from revascularization, whereas viable territories may influence symptoms and surgical strategy.
Palpitations, presyncope, and syncope may signal ventricular tachycardia. Sustained monomorphic ventricular tachycardia often arises from peri-scar reentry and may present months or years after infarction, even without visible worsening of the aneurysm; monomorphic tachycardia requires electrocardiographic documentation. Isolated premature beats do not demonstrate the same risk and must be interpreted with function, symptoms, and arrhythmic burden.

Stroke, acute limb ischemia, or splenic or renal infarction may result from embolization of ventricular thrombus. The event may be the first manifestation of the aneurysm, especially when the previous infarction was silent or was not followed by imaging; the embolic phenotype requires investigation for alternative sources. Atrial fibrillation, the aorta, and valves must be considered before attributing causality exclusively to the sac.
Physical examination may reveal a displaced impulse, third heart sound, mitral murmur, signs of congestion, and paradoxical precordial pulsation, but no finding is pathognomonic. The ECG often shows Q waves and persistent ST-segment elevation after a large anterior infarction, a suggestive but not diagnostic finding; persistent ST-segment elevation requires context. Active ischemia, pericarditis, and electrolyte abnormalities must be excluded when the picture changes.

Sudden pain, hypotension, syncope, or pericardial effusion are not expected features of a stable chronic true aneurysm; these signs require urgent reassessment for free rupture, pseudoaneurysm, a new coronary syndrome, or another emergency; signs of instability override reassurance from a previous diagnosis. The original images must be reviewed if the anatomical distinction was not documented.
Functional limitation must be quantified by symptom class, daily activities, and, in appropriate cases, cardiopulmonary testing. Peak oxygen consumption reflects output, chronotropic response, and conditioning and may help assess advanced heart failure; functional capacity complements anatomical measurements. A large sac in an active, stable patient is not equivalent to a smaller lesion associated with repeated hospitalizations.

Investigations and diagnosis

Transthoracic echocardiography identifies a thinned akinetic or dyskinetic region and quantifies volumes, ejection fraction, right ventricular function, and mitral regurgitation. It must describe location, extent, communication, motion, and the presence of thrombus, avoiding diagnosis based solely on a globular appearance. Initial echocardiography is accessible and repeatable. Nonforeshortened apical views are essential to avoid missing the distal portion of the sac.
Echocardiographic contrast improves endocardial border definition and thrombus detection when the apex is poorly visualized. Color Doppler assesses flow, but a broad nonrestrictive passage alone does not always distinguish aneurysm from pseudoaneurysm; cavity opacification reduces false findings caused by trabeculae. Equivocal imaging should lead to magnetic resonance or CT, not forced conclusions.

Magnetic resonance is the reference method for volumes, mass, and scar characterization. Late enhancement defines transmurality, viable tissue, and peri-scar channels, while dedicated sequences identify thrombus through absent perfusion and signal characteristics; cardiac magnetic resonance connects anatomy and substrate. It is particularly useful when revascularization, ablation, or surgical reconstruction is being discussed.
Cardiac CT offers high spatial resolution and describes calcification, thrombus, and relationships with the coronary arteries, diaphragm, and sternum. It is a valid alternative when magnetic resonance is contraindicated and helps plan reoperation, but involves iodinated contrast and radiation; cardiac tomography primarily answers anatomical questions. The acquisition phase must be suitable for evaluating the wall and cavity, not only the coronary arteries.

The most important differential diagnosis is post-infarction ventricular pseudoaneurysm. A broad transition, scarred myocardial wall, and anteroapical location support a true aneurysm; a narrow neck, abrupt myocardial interruption, and posterolateral location support a pseudoaneurysm without constituting absolute isolated criteria; myocardial continuity is the decisive principle. Numerical neck-to-sac ratios are only supporting elements.

Elements for diagnosing a true ventricular aneurysm

• Previous transmural infarction in the corresponding territory.
• Permanent dilation with wall akinesia or dyskinesia.
• Continuity of the myocardial layers, although thinned and scarred.
• Definition of volumes, residual function, mitral regurgitation, and viability.
• Targeted search for intracavitary thrombus and arrhythmic substrate.
• Exclusion of pseudoaneurysm when location or morphology is atypical.

Coronary angiography establishes anatomy and revascularization options; functional tests assess ischemia in viable myocardium. Ventriculography may show dyskinesia and contour but is used less because of noninvasive imaging and is not necessary for every diagnosis; coronary assessment is separate from demonstrating the sac. A treatable stenosis and a reconstructible cavity are questions with different evidence and benefits.
Holter monitoring, implantable devices, and electrophysiological study are selected according to symptoms and documented arrhythmias. Magnetic resonance may delineate scar channels useful for planning, but does not replace recording of the clinical rhythm; arrhythmic stratification integrates ejection fraction, syncope, and tachycardia. Serial aneurysm monitoring does not replace standard indications for a defibrillator.

Quantification must include indexed volumes, ejection fraction, stroke volume, right ventricular function, and regurgitation severity. Separating sac volume from the functional cavity may help the surgeon predict reconstruction results, although there is no single universally adopted method; the predicted residual volume is crucial. Excessive reduction may cause restrictive physiology, while insufficient correction leaves high wall stress.
Comparing examinations over time requires the same modality, consistent contours, and indexing to body surface area. Changes in preload or rhythm may alter volumes and regurgitation severity faster than scar structure, while plane differences alter sac measurement; serial comparability precedes interpretation of growth. When a change would determine surgery, images must be reviewed by an expert laboratory before defining true progression.

Treatment and prognosis

Basic therapy includes secondary prevention after infarction and guideline-directed heart failure treatment. Depending on the phenotype, neurohormonal antagonism, SGLT2 inhibitors, diuretics for congestion, blood pressure control, intensive lipid lowering, antiplatelet therapy, and rehabilitation are used; systemic therapy protects the remaining myocardium. No drug reconstructs a scar, but remodeling of viable regions may improve.
Anticoagulation is indicated when ventricular thrombus is documented, with drug selection and duration based on available evidence, bleeding risk, and follow-up imaging. A chronic aneurysm alone without thrombus does not mandate permanent anticoagulation; empirical prophylaxis remains selective. Triple therapy after PCI increases bleeding and requires reducing its duration when possible.

Residual ischemia is treated with antianginal therapy and revascularization when appropriate. Restoring flow to viable myocardium may improve symptoms and function, but does not transform transmural scar tissue into contractile muscle; myocardial viability assists complex planning. By itself it neither guarantees benefit nor automatically indicates a procedure.
Prevention of sudden death follows indications for ischemic heart disease and ejection fraction, observing the waiting period after infarction and revascularization when clinically possible. Sustained ventricular tachycardia may require a defibrillator, drugs, and scar ablation; an implantable cardioverter-defibrillator terminates malignant events but does not prevent every recurrence. Ablation reduces arrhythmic burden in selected patients and does not replace indicated protection.

Surgical ventricular reconstruction excludes the scarred region and restores a more physiological shape, often together with bypass and, when necessary, mitral treatment. Techniques include linear resection and endoventricular patch reconstruction, adapted to location and geometry; surgical restoration is not the same as simple aneurysmectomy. The risk is removing too much volume or leaving a cavity that remains inefficient.
In the STICH trial, systematically adding ventricular reconstruction to bypass reduced volumes more than bypass alone but did not improve death or cardiac hospitalization in the randomized population. The result precludes automatic use of the procedure without excluding benefit in highly selected patients with favorable anatomy and refractory symptoms. STICH evidence requires careful selection. Center experience and prediction of residual volume are decisive.

Considered indications include refractory heart failure or angina, uncontrollable ventricular tachycardias, recurrent embolism despite therapy, and a large sac that distorts an otherwise reconstructible cavity. Age, right ventricular function, mitral regurgitation, viability, comorbidities, and operative risk complete the decision; anatomical-functional selection must be collegial. Ventricular assist or transplantation may be more appropriate in end-stage phenotypes.
Prognosis is determined mainly by the myocardium that remains, not by the name of the lesion. High volumes, reduced ejection fraction, mitral regurgitation, ischemia, tachycardia, thrombus, and multivessel disease increase risk; individualized follow-up assesses symptoms, therapy, rhythm, and thrombus. Serial imaging is scheduled when a change may alter anticoagulation, device, or surgical strategy.

Physical activity is resumed through graded rehabilitation after unstable ischemia, uncontrolled arrhythmias, and heart failure have been excluded. There is no universal prohibition based solely on the presence of the sac, whereas competitive or high-intensity exercise requires specific assessment; exercise prescription considers capacity, blood pressure, and rhythm. Deconditioning worsens symptoms and quality of life without providing demonstrated structural protection.
Shared decision-making must present expected benefit, operative mortality, the possibility of residual symptoms, and alternatives separately. Observational data from expert centers are not directly transferable to every anatomy, and the average STICH result does not predict every individual candidate. Therapeutic uncertainty must be explicit. Patient preferences matter after a realistic collegial estimate, not instead of technical assessment.

Thrombus follow-up uses contrast echocardiography or magnetic resonance according to quality and availability. Disappearance permits discussion of discontinuation after the planned period, whereas persistence, organization, and mobility require reassessment of adherence, drug, and risk; anticoagulant response is not inferred solely from elapsed months. Interactions with dual antiplatelet therapy, anemia, and previous bleeding must be reassessed at every therapeutic transition.

Complications

Pump dysfunction may progress to heart failure with reduced ejection fraction, congestion, and hypoperfusion. Dilation and mitral regurgitation form a cycle that increases pressures, dimensions, and symptoms until the right ventricle is compromised; progressive remodeling is not inevitable. Adequate therapy, blood pressure control, and prevention of new ischemia may stabilize or improve the viable ventricle.
Ventricular tachycardia may be incessant or recurrent or cause electrical storms. Repeated defibrillator shocks worsen quality of life and function, making correction of triggers, drugs, sedation, and ablation at expert centers necessary; an electrical storm is a complex emergency. Electrolytes, ischemia, and heart failure must be treated together with the scar circuit.

Ventricular thrombus may embolize, causing stroke or systemic ischemia. Protruding or mobile thrombi are of greater concern, but a laminated formation may also be relevant; magnetic resonance identifies thrombi not visible on noncontrast echocardiography; embolic risk changes during organization and therapy. Documented resolution permits reassessment of anticoagulation duration.
Mitral regurgitation may worsen with dilation and papillary displacement, causing pulmonary edema and hospitalization. Correcting only the valve without considering geometry, ischemia, and function may leave intact the mechanism that distorts it; the ischemic mitral valve is a ventricular as well as valvular disease. The strategy integrates therapy, revascularization, and intervention when indicated.

Angina may persist because of unrevascularized coronary disease or high demand from the remaining myocardium. New pain at rest must be managed as a possible acute coronary syndrome and not automatically attributed to the known aneurysm; recurrent ischemia may accelerate deterioration. ECG, troponin, and anatomy are reassessed according to urgency and clinical probability.
Rupture of a chronic true aneurysm is rare because the fibrous wall is relatively resistant. A diagnosis of rupture, hemopericardium, or rapid expansion should raise suspicion of a subacute lesion, pseudoaneurysm, or incorrect initial classification; late rupture is not the dominant complication. Using it as the principal justification for elective surgery overestimates natural risk.

Surgical complications include bleeding, low output, arrhythmias, renal failure, stroke, and a residual cavity that is too small or remains dilated. A patch may modify the substrate but does not eliminate the entire scar or every thrombotic risk; postoperative geometry must be verified by imaging. Secondary prevention, heart failure therapy, and arrhythmic control continue after surgery.
Anxiety after defibrillator shocks, fear of embolism, and reduced activity may impair quality of life independently of volumes. Cardiac rehabilitation, symptom education, and psychological support aid recovery without minimizing clinical risk; the psychological burden is a real consequence. Activity goals must be personalized to functional capacity and not to the anatomical presence of the aneurysm alone.

Severely reduced ventricular function also predisposes to venous thrombosis, hepatic congestion, kidney disease, and frailty, which affect anticoagulation and surgical candidacy. Late treatment of these systemic consequences offers less opportunity than early titration of cardiac therapy; multiorgan progression signals advanced disease. Assessment for ventricular assist or transplantation should not be delayed until irreversible failure of other organs occurs.